The antiarrhythmic medicine sales in Austria are forecasted to decline steadily from 2024 to 2028, starting at 5.6 million USD in 2024 and decreasing to 4.1 million USD by 2028. In 2023, actual sales stood at 6.0 million USD. This represents a year-on-year percentage decrease of approximately 6.7% in 2024 compared to 2023. The compounded annual growth rate (CAGR) over the last five years (2024-2028) is a decrease of approximately 6.3% per year.
Future trends to watch for include shifts in regulatory policies, advancements in alternative treatments, and potential new market entrants. Additionally, the increasing adoption of digital health technologies and personalized medicine could significantly impact the market dynamics for antiarrhythmic medications.
